What this page helps you do
Prepare a precise Uzbekistan hematology file for CAR-T evaluation while keeping age, disease target and local care central to every decision.
- Before hospital review
- Confirm whether the referral concerns an adult or child and include the exact diagnosis, target-marker evidence, prior treatment, response and current clinical stability.
- Documents
- Preserve original Uzbek or Russian reports and provide requested translations of pathology, molecular testing, marrow, imaging and treatment response.
- Travel
- Published short-stay exemption is a general entry rule, not confirmation of permission or readiness to travel for treatment. Reconfirm the medical-purpose route and expected duration.
- Continuity of care
- Identify the local hematology or oncology team responsible for bridging care, infections, blood counts and urgent decisions while specialist evaluation is pending.
- National oncology and hematology plans do not prove patient-level CAR-T availability in Uzbekistan or Turkey.
- Hospital evaluation is not confirmed treatment availability for an international patient; product, manufacturing, capacity and clinical suitability remain case-specific.
- General entry rules do not themselves authorize medical travel.
Travel information checked 11 October 2026. Reconfirm requirements before booking.
Begin With a Case-Specific Clinical Question
CAR-T Cell Therapy is considered only for selected relapsed or refractory hematologic malignancies after specialist review. A diagnosis of leukemia, lymphoma or multiple myeloma does not by itself establish eligibility.
The exact indication, target, product and campus availability must be confirmed for the individual case. Publication of this pathway does not promise eligibility, manufacturing access, timing, price or outcome.
Hematology Care in Uzbekistan and CAR-T Review Are Separate
Uzbekistan has current national planning for oncology and hematology services, including a 2026–2035 plan for children and adolescents. National service development does not establish CAR-T availability for a particular adult or child, and age-appropriate local specialists must remain responsible for active care.
This page does not claim that CAR-T Cell Therapy is unavailable in Uzbekistan. It also does not infer that a published Turkish hospital program is currently available to an international patient.
Acibadem Altunizade Is the Featured Partner Route
MedTransplant can coordinate preliminary review through the featured Acibadem route while the responsible specialists confirm the indication, suitable campus and current product pathway.
Patients may also ask to compare other suitable verified programs; Acibadem is not presented as the only option.
Prepare the Hematology File in Uzbekistan
The hospital needs an exact, chronological record rather than a general diagnosis label.
- Current specialist summary with disease subtype
- Pathology, flow cytometry, molecular and target-marker results
- Prior systemic therapies, dates and response
- Recent imaging, marrow and laboratory reports
- Current complications, infections and medicines
- Key Uzbek or Russian pathology and molecular records translated only when requested
- Age-appropriate treating-team contact and current stabilization plan
What Specialist Review May Address
The team may assess disease target, prior therapies, current disease control, performance status, organ function, infection risk, potential alternatives and whether cell collection and manufacturing are feasible.
Understand the CAR-T Cell Therapy Sequence
If further evaluation is appropriate, the pathway may include confirmatory testing, cell collection, manufacturing, possible bridging treatment, lymphodepletion, infusion and close monitoring. Each stage remains conditional.
Plan for Intensive Monitoring
Potential immune, neurologic, infectious and blood-count complications require an experienced team, rapid access to urgent care and a clear caregiver plan.
Coordinate Safe Travel From Uzbekistan
Clarify companion, accommodation and medical-continuity needs only after specialists identify a clinically realistic next step and confirm whether an age-appropriate pathway can be evaluated.
Do not make non-refundable bookings until meaningful specialist feedback identifies the next step. Seek local urgent care if the patient becomes unstable.
Connect the Home and Treating Teams
Before travel, identify the local hematology or oncology team that can share records and support monitoring after return. Ask both teams how urgent questions and late complications will be handled.
Request a Program Comparison
MedTransplant can help compare suitable verified programs using the same clinical file. Comparison does not guarantee that another center will accept the case or have a relevant product available.
No Eligibility, Availability, Price or Outcome Promise
Only the treating specialists can decide whether CAR-T Cell Therapy should be considered. Any availability or cost information must be confirmed case by case and may change during evaluation.
Continue With the Acibadem CAR-T Cell Therapy Guide
Review the featured program route, clinical selection boundaries, risks, records and comparison option.
Explore CAR-T Cell Therapy review at Acibadem AltunizadeFrequently Asked Questions
Who may be considered for CAR-T Cell Therapy?
Only selected patients with particular relapsed or refractory hematologic malignancies may be considered after specialist review of the exact diagnosis, target, prior treatments, disease status and overall health.
Does a leukemia, lymphoma or myeloma diagnosis mean CAR-T Cell Therapy is needed?
No. Many patients receive other therapies. A hematology or oncology team must compare CAR-T Cell Therapy with other standard, investigational or supportive options for the individual case.
Does the featured Acibadem route guarantee acceptance or product availability?
No. The responsible specialist team must confirm whether it can evaluate the case and whether an appropriate product and treatment pathway are available at the required time.
Which records are useful for preliminary review?
A current hematology summary, pathology and molecular reports, treatment history, response assessments, recent imaging or marrow results, blood counts, organ-function tests and infection information are commonly useful.
Why is close monitoring required?
CAR-T Cell Therapy can cause serious immune, neurologic, infectious and hematologic complications. The treating center must explain monitoring, emergency response and follow-up requirements.
Can MedTransplant compare other programs?
Yes. Acibadem Altunizade is the featured partner route for this campaign, not the patient’s only option. MedTransplant can help request comparison with other suitable verified programs.
Sources and verification
- Acibadem Altunizade Hospital
- Acibadem: CAR-T Cell Therapy
- Acibadem: CAR-T Cell Therapy for Leukemia, Lymphoma and Myeloma
- NCI: CAR T Cells—Engineering Immune Cells to Treat Cancer
- FDA: CAR-T Cell Therapy safety communication for BCMA- and CD19-directed immunotherapies
- Uzbekistan Ministry of Health: National oncology and hematology plan 2026–2035
- Uzbekistan government: Oncology and palliative-care system development
- Türkiye Ministry of Foreign Affairs: Visa information for foreigners
- Türkiye Ministry of Foreign Affairs: General information about Turkish visas
Clinical responsibility
MedTransplant coordinates case preparation and referral. Hematology and oncology specialists make every diagnosis, eligibility, product, treatment, monitoring and acceptance decision.
